Advances in nanotechnology-based delivery systems for curcumin

Nanomedicine

Volumn 7, Issue 7, 2012, Pages 1085-1100

  Sun, Min ^a,b   Su, Xun ^a   Ding, Buyun ^a   He, Xiuli ^c   Liu, Xiuju ^d   Yu, Aihua ^a   Lou, Hongxiang ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b Central Hospital of Zibo   (China)

^c Affiliated Hospital of Shandong Medical Institution   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

bioavailability; biological activity; curcumin; nanotechnology

Indexed keywords

APREPITANT; BOVINE SERUM ALBUMIN; CHITIN; CISPLATIN; CURCUMIN; CYCLODEXTRIN; DENDRIMER; DIMER; EUDRAGIT; FENOFIBRATE; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MEGESTROL ACETATE; NANOCRYSTAL; OVALBUMIN; POLYGLACTIN; POLYMER; RAPAMYCIN; SOLID LIPID NANOPARTICLE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG IMPLANT; DRUG SOLUBILITY; HUMAN; HYDROGEL; HYDROPHILICITY; HYDROPHOBICITY; MAXIMUM PLASMA CONCENTRATION; MICELLE; NANOEMULSION; NANOPHARMACEUTICS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CURCUMA; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS;

EID: 84864430063     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.80     Document Type: Review

References (101)

1. Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int. J. Pharm. 244(1-2), 127-135 (2002). (Pubitemid 35245453)
2. Wang YJ, Pan MH, Cheng AL et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 15(12), 1867-1876 (1997).
3. Ireson CR, Jones DL, Orr S et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 11(1), 105-111 (2002). (Pubitemid 34118319)
4. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rats. Xenobiotica 8(12), 761-768 (1978). (Pubitemid 9119050)
5. Ravindranath V, Chandrasekhara N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology 20(2-3), 251-257 (1981). (Pubitemid 11117911)
6. Ireson C, Orr S, Jones DJ et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 61(3), 1058-1064 (2001). (Pubitemid 32174425)
7. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch. Physiol. Biochem. 114(2), 127-149 (2008). (Pubitemid 351892715)
8. Anand P, Thomas SG, Kunnumakkara AB et al. Biological activities of curcumin and its analogues (congeners) made by man and mother nature. Biochem. Pharmacol. 76(11), 1590-1611 (2008).
9. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4(6), 807-818 (2007).
10. Lao CD, Ruffn MT, Normolle D et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 6, 10 (2006).
11. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269(2), 199-225 (2008).
12. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett. 255, 170-181 (2007). (Pubitemid 47268637)
13. Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT 116 human colon cancer cells. Carcinogenesis 252, 2183-2189 (2004). (Pubitemid 39534856)
14. Scott DW, Loo G. Curcumin-induced GADD 153 gene up regulation in human colon cancer cells. Carcinogenesis 25, 2155-2164 (2004). (Pubitemid 39534853)
15. Lev-Ari S, Strier L, Kazanov D et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 11, 6738-6744 (2005). (Pubitemid 41339017)
16. Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 9, 147-152 (2006). (Pubitemid 43970963)
17. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59(7), 631-644 (2007). (Pubitemid 47285408)
18. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 17(1-2), 71-80 (2012).
19. Immordino ML, Dosio F, Cattel L. Liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1(3), 297-315 (2006).
20. Webb MS, Johnstone S, Morris TJ et al. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur. J. Pharm. Biopharm. 65(3), 289-299 (2007).
21. Hwang TL, Lee WR, Hua SC, Fang JY. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas. J. Dermatol. Sci. 46(1), 11-20 (2007).
22. Xiong Y, Guo D, Wang L, Zheng X, Zhang Y, Chen J. Development of nobiliside A loaded liposomal formulation using response surface methodology. Int. J. Pharm. 371(1-2), 197-203 (2009).
23. Zhai G, Wu J, Zhao X et al. A liposomal delivery vehicle for the anticancer agent gossypol. Anticancer Res. 28(5A), 2801-2805 (2008).
24. Sethi V, Onyuksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol. 391, 377-395 (2005). (Pubitemid 40254046)
25. Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J. Agric. Food Chem. 57(19), 9141-9146 (2009).
26. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 125(1), 1-8 (2009).
27. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int. J. Oncol. 32(5), 1119-1123 (2008).
28. Wang D, Veena MS, Stevenson K et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor KB by an AKT-independent pathway. Clin. Cancer Res. 14(19), 6228-6236 (2008).
29. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104(6), 1322-1331 (2005). (Pubitemid 41282806)
30. Arbiser JL, Klauber N, Rohan R et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med. 4(6), 376-383 (1998). (Pubitemid 28387896)
31. Chen C, Johnston TD, Jeon H et al. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int. J. Pharm. 366(1-2), 133-139 (2009).
32. Sullivan CO, Birkinshaw C. In vitro degradation of insulin-loaded poly (N-butylcyanoacrylate) nanoparticles. Biomaterials 25(18), 4375-4382 (2004). (Pubitemid 38388598)
33. Farion K, Osmond MH, Hartling L et al. Tissue adhesives for traumatic lacerations in children and adults. Cochrane Database Syst. Rev. 3, CD003326 (2002).
34. Sun M, Gao Y, Guo CY et al. Enhancement of transport of curcumin to brain in mice by poly(N-butylcyanoacrylate) nanoparticle. J. Nanopart. Res. 12(8), 3111-3122 (2010).
35. Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against b amyloid induced cytotoxicity using in vitro cell culture model. Mol. Pharm. 7(3), 815-825 (2010).
36. Duan J, Zhang Y, Han S et al. Synthesis and in vitro/in vivo anticancer evaluation of curcumin-loaded chitosan/poly(butylcyanoacrylate) nanoparticles. 400(1-2), 211-220 (2010).
37. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 37(3-4), 223-230 (2009).
38. Anand P, Nair HB, Sung B et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem. Pharmacol. 79(3), 330-338 (2010).
39. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian Res. 3, 11 (2010).
40. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM. Partial correction of cystic fbrosis defects with PLGA nanoparticles encapsulating curcumin. Mol. Pharm. 7(1), 86-93 (2009).
41. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J. Colloid Interface Sci. 351(1), 19-29 (2010).
42. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 29(10), 3867-3875 (2009).
43. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM. Partial correction of cystic fbrosis defects with PLGA nanoparticles encapsulating curcumin. Mol. Pharm. 7(1), 86-93 (2010).
44. Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem. Pharm. Bull. 58(11), 1423-1430 (2010).
45. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 6(1), 153-160 (2010).
46. Akhtar F, Rizvi MM, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol. Adv. 30(1), 310-320 (2012).
47. Kumar A, Glaum M, El-Badri N. Initial observations of cell-mediated drug delivery to the deep lung. Cell Transplant. 20(5), 609-618 (2011).
48. Anitha A, Maya S, Deepa N et al. Effcient waters soluble O-carboxymethyl chitosan nanocarrier for the delivery of curcumin to cancer cells. Carbohydrate Polymers 83 (2), 452-461 (2011).
49. Anitha A, Maya S, Chennazhi KP, Nair SV, Tamura H, Jayakumar R. Curcumin loaded N, O-carboxymethyl chitosan nanoparticles for cancer drug delivery. J. Biomater. Sci-Polymer Edition doi:org/10.1163/0920506 11X581534 (2012) (Epub ahead of print).
50. Sanoj Rejinold N, Muthunarayanan M, Divya Rani VV et al. Curcumin loaded biocompatible thermo-responsive polymeric nanoparticles for cancer drug delivery J. Colloid Interface Sci. 360(1), 39-51 (2011).
51. Sanoj Rejinold N, Sreerekha PR, Chennazhi KP, Nair SV, Tamura H, Jayakumar R. Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly (N-isopropylacrylamide) nanocarrier for curcumin drug delivery. Int. J. Biol. Macromol. 49(2), 161-172 (2011).
52. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control Release. 157(2), 168-182 (2012).
53. Patil GV. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev. Res. 58, 219-247 (2003). (Pubitemid 36555058)
54. Kim TH, Jiang HH, Youn YS et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int. J. Pharm. 403(1-2), 285-291 (2011).
55. Prajakta D, Ratnesh J, Chandan K et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J. Biomed. Nanotechnol. 5(5), 445-455 (2009).
56. Dandekar P, Dhumal R, Jain R, Tiwari D, Vanage G, Patravale V. Toxicological evaluation of pH-sensitive nanoparticles of curcumin: acute, sub-acute and genotoxicity studies. Food Chem. Toxicol. 48(8-9), 2073-2089 (2010).
57. Shelma R, Sharma CP. Acyl modifed chitosan derivatives for oral delivery of insulin and curcumin. J. Mater. Sci. Mater. Med. 21, 2133-2140 (2010).
58. Shamji MF, Hwang P, Bullock RW, Adams SB, Nettles DL, Setton LA. Release and activity of anti-TNFa therapeutics from injectable chitosan preparations for local drug delivery. J. Biomed. Mater. Res. B. Appl. Biomater. 90(1), 319-326 (2009).
59. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol. Nutr. Food Res. 54, 1-9 (2010).
60. Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int. J. Pharm. 398(1-2), 190-203 (2010).
61. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond.) 5(3), 433-449 (2010).
62. Gou M, Men K, Shi H et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 3(4), 1558-1567 (2011).
63. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly(ethyleneoxide)-b-poly(e-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J. Biomed. Mater. Res. A. 86(2), 300-310 (2008). (Pubitemid 351969628)
64. Song Z, Feng R, Sun M et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J. Colloid Sci. 354(1), 116-123 (2011).
65. Raemdonck K, Demeester J, Smedt DS. Advanced nanogel engineering for drug delivery. Soft Matter 5, 707-715 (2009).
66. Wu W, Shen J, Banerjee P, Zhou S. Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy. Biomaterials 32(2), 598-609 (2011).
67. Dandekar PP, Jain R, Patil S et al. Curcumin-loaded hydrogel nanoparticles: application in anti-malarial therapy and toxicological evaluation. J. Pharm. Sci. 99(12), 4992-5010 (2010).
68. Mangalathillam S, Rejinold NS, Nair A, Lakshmanan VK, Nair SV, Jayakumar R. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale 4(1), 239-250 (2012).
69. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62(1), 3-16 (2006). (Pubitemid 41736019)
70. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Deliv. Rev. 47(1), 3-19 (2001). (Pubitemid 32209229)
71. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 36(1), 43-48 (2008).
72. Gao Y, Li Z, Sun M et al. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv. 18(2), 131-142 (2011).
73. Gao Y, Li Z, Sun M et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev. Ind. Pharm. 36(10), 1225-1234 (2010).
74. Onoue S, Takahashi H, Kawabata Y et al. Formulation design and photochemical studies of nanocrystal solid dispersion of curcumin with improved oral bioavailability J. Pharm. Sci. 99(4), 1871-1881 (2010).
75. Podlogar F, Gasperlin M, Tomsic M, Jamnik A, Rogac MB. Structural characterization of water-Tween40/Imwitor 308-isopropyl myristate microemulsions using different experimental methods. Int. J. Pharm. 276(1-2), 115-128 (2004). (Pubitemid 38548840)
76. He L, Wang GL, Zhang Q. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profle. Int. J. Pharm. 250(1), 45-50 (2003). (Pubitemid 35447936)
77. Seki J, Sonoke S, Saheki A, Fukui H, Sasaki H, Mayumi T. A nanometer lipid emulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int. J. Pharm. 273(1-2), 75-83 (2004). (Pubitemid 38317042)
78. Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta DA. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug. Deliv. Rev. 62(4-5), 547-559 (2010).
79. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 358(1-2), 285-291 (2008).
80. Mou D, Chen H, Du D et al. Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs. Int. J. Pharm. 353(1-2), 270-276 (2008).
81. Cui J, Yu B, Zhao Y et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int. J. Pharm. 371(1-2), 148-155 (2009).
82. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur. J. Pharm. Biopharm. 76(3), 475-485 (2010).
83. Wu X, Xu J, Huang X, Wen C. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability SMEDDS improves curcumin dissolution and bioavailability. Drug Dev. Ind. Pharm. 37(1), 15-23 (2011).
84. Lin CC, Lin HY, Chen HC, Yu WM, Lee MH. Stability and characterization of phospholipid-based curcumin-encapsulated microemulsions. Food Chem. 116(4), 923-928 (2009).
85. Semalty A, Semalty M, Rawat MS, Franceschi F. Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals. Fitoterapia 81(5), 306-314 (2010).
86. Cucuzza LS, Motta M, Miretti S, Accornero P, Baratta M. Curcuminoid-phospholipid complex induces apoptosis in mammary epithelial cells by STAT-3 signaling. Exp. Mol. Med. 40(6), 647-657 (2008).
87. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330(1-2), 155-163 (2007). (Pubitemid 46097368)
88. Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J. Pharm. Biomed. Anal. 40(3), 720-727 (2006). (Pubitemid 43227396)
89. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward W P, Gescher AJ. Comparison of systemic availability of curcumin with thaof curcumin formulated with phosphatidylcholine. Cancer Chemother. Pharmacol. 60(2), 171-177 (2007). (Pubitemid 46742531)
90. Gupta NK, Dixit VK. Bioavailability enhancement of curcumin by complexation with phosphatidyl choline. J. Pharm. Sci. 100(5), 1987-1995 (2011).
91. Yadav VR, Suresh S, Devi K, Yadav S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-infammatory activity in rat colitis mode. AAPS Pharm. Sci. Tech. 10(3), 752-762 (2009).
92. Yallapu MM, Jaggi M, Chauhan SC. b-cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf. B. Biointerfaces 79(1), 113-125 (2010).
93. Yallapu MM, Jaggi M, Chauhan SC. Poly(β-cyclodextrin)/curcumin self-assembly: a novel approach to improve curcumin delivery and its therapeutic effcacy in prostate cancer cells. Macromol. Biosci. 10(10), 1141-1151 (2011).
94. Salmaso S, Bersani S, Semenzato A, Caliceti P. New cyclodextrin bioconjugates for active tumour targeting. J. Drug Target. 15(6), 379-390 (2007). (Pubitemid 47073053)
95. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 71(3), 445-462 (2009).
96. Shi W, Dolai S, Rizk S et al. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org. Lett. 9(26), 5461-5464 (2007).
97. Fung LK, Saltzman WM. Polymericimplants for cancer chemotherapy. Adv. Drug Deliv. Rev. 26(2-3), 209-230 (1997).
98. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev. Res. 4(8), 1158-1171 (2011).
99. Wadee A, Pillay V, Choonara YE et al. Recent advances in the design of drug-loaded polymeric implants for the treatment of solid tumors. Expert Opin. Drug Deliv. 8(10), 1323-1340 (2011).
100. Bansal SS, Vadhanam MV, Gupta RC. Development and in vitro-in vivo evaluation of polymeric implants for continuous systemic delivery of curcumin. Pharm. Res. 28(5), 1121-1130 (2011).
101. Bansal SS, Kausar H, Vadhanam MV, Ravoori S, Gupta RC. Controlled systemic delivery by polymeric implants enhances tissue and plasma curcumin levels compared with oral administration. Eur. J. Pharm. Biopharm. 80, 571-577 (2012).